COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 186 participants.

Also called NCT07245680

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 186 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07245680
  • EU CT 2023-509891-40-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07245680. Randomized; triple masking; primary purpose treatment. Start 2026-04-28 (actual); primary completion 2029-02-14 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular Comorbidities
Acronym
COMMODITIES
Condition
Pulmonary Arterial Hypertension (PAH)
Condition
Comorbidities
Condition
Cardiovascular Disease (CVD)
Intervention (Drug)
Tadalafil
Intervention (Drug)
Ambrisentan
Intervention (Drug)
Placebo (Ambrisentan-matching)
Lead sponsor
Assistance Publique - Hôpitaux de Paris (class: other)

Record details

Record id
cardio:ct-nct07245680
Content hash
469d1197d0f345244391a8ec99e1053b55123ba0d9f1abb3756a0cb8aef22181